#DDDD

Phenomenal Presentation by 4D and Key Opinion Leaders

With some very subtle, yet VERY STRONG messages about MRx

#DDDD

Firstly, they was thrilled with the fact Mrx0518 on its own showed
Strong Anti Tumour Bio Marker Activity
with up regulation of the MOST POTENT cancer fighting Bio Marker IL-12 along with other anti cancer bio markers

#DDDD

Coupled with the down regulation of Neutrophils and Treg Cells.

These Cells are witnessed in abundance with cancer patients with the worst outcomes

Therefore by reducing these bio markers signals again anti tumour properties

#DDDD

By reducing Treg cells (homeostasis cells) it allows over abundance/ production of the anti tumour cells which allow the immune system to fight the tumour

Yet MRx0518 has an excellent safety profile leading me to believe this approach is better than CAR-T Cell therapy

#DDDD

Without going into too much detail this is very promising EARLY signs for MRx0518

So far every cancer indication which has had a meaningful enrolment has seen very positive effects

Lung
Kidney

Now Positive indications showing for Breast Cancer

#DDDD

Now @4dpharmaplc in conjunction with @Merck have decided to begin a HUGE 'LAND GRAB'/ EXPANSION into 6 cancer types proving out Mrx0518

-Lung
-Kidney
-Bladder
-Breast
-Head and Neck
-Microsatellite

As I have said the next 12 months will be the making of 4D pharma

#DDDD

4D are targeting accelerated approval for MRx0518 as I have previously discussed outlining the revenue potential for only one small indication of terminal cancer
$3.52 BILLION
https://twitter.com/AimHardy/status/1319541781256720385?s=20

Think of the potential if this is opened up to multiple indications

#DDDD

Now if you are wondering how close may this therapy make it to market?

4D are consulting with the FDA Q1 2021 to review an accelerated approval pathway

This will be a very significant meeting and when Duncan was question he hinted it may be around a 2 year time frame

#DDDD

What also sparked my attention, which I believe to be a massive deal, was the repeated focus that

Pre clinical bio markers of MRx0518 matched clinical In Human bio markers

Validating that what they are seeing in the Lab directly correlates with the immune response

#DDDD

They repeatedly emphasised this STRONGLY mirrored analysis validates the whole MRx platform

This means there is a high likelihood that

-Asthma
-COVID
-Parkinsons

Trials are all VERY likely to show safe and efficacious RESULTS

#DDDD

I have already produced analysis on the bio markers for each of these indications which show

Strong immunomodulatory results favouring positive clinical outcomes for patients in these indications

#DDDD

Duncan has repeatedly shown excitement for MRx in CNS diseases like Parkinson's Disease

Specifically even mentioning it in a talk which was completely revolved around Cancer

This to me is a subtle indication they believe they may have found something VERY POWERFUL

#DDDD

You have to remember... This is just the start for Live Bio Therapeutics

A completely new novel class of Therapeutics.

Something which 4D is a world leader in with MASSIVE IP

I will leave you with this article explained very well by the CEO https://twitter.com/AimHardy/status/1319301980947423233?s=20

#DDDD

People seem to just not quite grasp the context of all the aforementioned, coupled with the imminent NASDAQ listing which will COMPLETELY put this valuation in a different paradigm than to what it currently is

#NCYT (176) #EUA (83) #GGP (158) Style Rise IMO

#DDDD